MKI67 and neoplasm: Meng et al. developed a radiomic model from MRI datasets of 345 patients with RC taking into account multiple factors, such as lymph node metastasis, tumor differentiation grade, a fraction of Ki-67-positive tumor cells, human epidermal growth factor receptor 2 (HER-2) expression and KRAS-2 gene mutation status, yielding an AUC of 0.699 for signatures evaluating Ki-67 and of 0.697 for an integrated evaluation model incorporating radiomics signature and MRI-reported lymph node status [27].